PFE

EX-99

2 pfe-9272026xex99.htm

EX-99

Document

Exhibit 99

Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance

■Focused Execution Drove 32% Operational Revenue Growth of Launched and Acquired Products(1)

■Advancing Robust Late-Stage Pipeline with Multiple Key Catalysts Ahead

■Raises 2026 Guidance(2) on Strong Year-to-Date Performance

■Appoints Cecile Guegan Chief Financial Officer, Executive Vice President

NEW YORK, Tuesday, November 3, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS.

EXECUTIVE COMMENTARY

Dr. Albert Bourla, Chairman and CEO of Pfizer:

"Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, I believe we're well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead."

Cecile Guegan, CFO and EVP of Pfizer:

“Our third-quarter results reflect strong commercial performance globally and continued operational discipline. This quarter, our non-COVID products delivered strong 7% operational revenue growth, and I’m particularly pleased with the 32% year-over-year operational revenue growth from our launched and acquired products(1). Today, we are raising our full-year 2026 Revenue and Adjusted diluted EPS guidance, reflecting our strong year-to-date performance and confidence in our business.”

OVERALL RESULTS

■Third-Quarter 2026 Revenues of $16.6 Billion, Relatively Flat Year-over-Year Operationally

–Excluding Contributions from Comirnaty and Paxlovid, Revenues Grew 7% Operationally

–Revenues of Launched and Acquired Products(1) Grew 32% Operationally

■Third-Quarter 2026 Reported(4) Diluted EPS of $0.56, and Adjusted(3) Diluted EPS of $0.87

■Raises Full-Year 2026 Revenue Guidance(2) by $1.5 billion at the Midpoint to a Range of $62.0 to $64.0 billion

■Raises and Narrows Full-Year 2026 Adjusted(3) Diluted EPS Guidance to a Range of $2.95 to $3.05

■Recent Late-Stage Pipeline Progress Includes Eight Key Pivotal Study Starts, One Pivotal Readout and Two Regulatory Decisions

- 1 -

Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates(5).

Results for the third quarter and first nine months of 2026 and 2025(6) are summarized below.

($ in millions, except per share amounts) Third-QuarterNine Months

20262025 % Change 20262025 % Change

Revenues$ 16,583 $ 16,654 —$  46,067 $  45,022 2%

Reported(4) Net Income 3,242 3,541 (8%)5,681 9,419 (40%)

Reported(4) Diluted EPS 0.56 0.62 (9%)0.99 1.65 (40%)

Adjusted(3) Income 4,985 4,949 1%13,715 14,620 (6%)

Adjusted(3) Diluted EPS 0.87 0.87 —2.39 2.56 (7%)

REVENUES

($ in millions)Third-QuarterNine Months

20262025% Change20262025% Change

TotalOper.TotalOper.

Global Biopharmaceuticals Business (Biopharma)$ 16,283 $ 16,310 ——$ 45,105 $ 44,056 2%1%

Pfizer CentreOne 300 344 (13%)(12%)962 966 —(2%)

TOTAL REVENUES$ 16,583 $ 16,654 ——$ 46,067 $ 45,022 2%1%

- 2 -

2026 FINANCIAL GUIDANCE(2)

■Raises full-year 2026 Revenue guidance(2) by $1.5 billion at the midpoint to a range of $62.0 to $64.0 billion from $60.5 to $62.5 billion previously.

■Raises and narrows full-year 2026 Adjusted(3) diluted EPS guidance(2) to a range of $2.95 to $3.05 from $2.80 to $3.00 previously.

–Includes a one-time $650 million Acquired In-Process R&D charge related to the in-licensing and collaboration agreement with Innovent Biologics, Inc. recorded in the third quarter of 2026 with an unfavorable impact of approximately $0.10.

■The company’s guidance takes into consideration our strong year-to-date performance, continued confidence in our business and progress with ongoing cost improvement initiatives.

Revenues $62.0 to $64.0 billion

(previously $60.5 to $62.5 billion)

Adjusted(3) SI&A Expenses

$12.5 to $13.5 billion

Adjusted(3) R&D Expenses

$10.8 to $11.8 billion

(previously $10.5 to $11.5 billion)

Effective Tax Rate on Adjusted(3) Income

Approximately 15.0%

Adjusted(3) Diluted EPS

$2.95 to $3.05

(previously $2.80 to $3.00)

CAPITAL ALLOCATION

During the first nine months of 2026, Pfizer deployed its capital in a variety of ways, which primarily included:

■Reinvesting capital into initiatives intended to enhance the future growth prospects of the company, including:

–$8.3 billion invested in internal research and development projects, and

–Approximately $850 million invested in business development transactions, primarily reflecting the Innovent Biologics, Inc. in-licensing

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1785967452.c8df62f5

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

EX-99

2 pfe-3292026xex99.htm

EX-99

Document

Exhibit 99

g

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

■Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1)

■Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage Readouts

■Robust Late‑Stage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026

NEW YORK, Tuesday, May 5, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2).

EXECUTIVE COMMENTARY

Dr. Albert Bourla, Chairman and CEO of Pfizer:

“We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and encouraging mid-stage results building meaningful momentum – and I'm particularly encouraged by what we're seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead.”

David Denton, CFO and EVP of Pfizer:

“Our first-quarter results are attributable to our solid commercial performance globally as well as our ongoing focus on operational efficiency. This quarter, I’m particularly pleased with the 22% year-over-year operational revenue growth from our launched and acquired products(1). Today, we are reaffirming our full-year 2026 financial guidance.”

OVERALL RESULTS

■First-Quarter 2026 Revenues of $14.5 Billion, Representing 2% Year-over-Year Operational Growth

–Excluding Contributions from Comirnaty and Paxlovid, Revenues Grew 7% Operationally

–Revenues of Launched and Acquired Products(1) Grew 22% Operationally

■First-Quarter 2026 Reported(3) Diluted EPS of $0.47, and Adjusted(4) Diluted EPS of $0.75

■Reaffirms All Components of Full-Year 2026 Financial Guidance(2), including Revenues in a Range of $59.5 to $62.5 Billion and Adjusted(4) Diluted EPS in a Range of $2.80 to $3.00

- 1 -

Beginning in the first quarter of 2026, we made organizational changes in our commercial organization within the Global Biopharmaceuticals Business (Biopharma) to better support and optimize performance across our product portfolios. These changes include the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio and the creation of a new Global Hospital and Biosimilars Division within Biopharma. See the Item 1. Business––Commercial Operations section of Pfizer's 2025 Annual Report on Form 10-K (available at www.pfizer.com and www.sec.gov).

Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates(5).

Results for the first quarter of 2026 and 2025(6) are summarized below.

($ in millions, except per share amounts) First-Quarter

20262025 % Change

Revenues$ 14,451 $ 13,715 5%

Reported(3) Net Income 2,687 2,967 (9%)

Reported(3) Diluted EPS 0.47 0.52 (10%)

Adjusted(4) Income 4,290 5,237 (18%)

Adjusted(4) Diluted EPS 0.75 0.92 (18%)

REVENUES

($ in millions)First-Quarter

20262025% Change

TotalOper.

Global Biopharmaceuticals Business (Biopharma)$ 14,161 $ 13,441 5%2%

Pfizer CentreOne 289 273 6%1%

TOTAL REVENUES$ 14,451 $ 13,715 5%2%

- 2 -

2026 FINANCIAL GUIDANCE(2)

■Reaffirms all components of full-year 2026 Financial Guidance(2), including Revenues in a range of $59.5 to $62.5 billion and Adjusted(4) Diluted EPS in a Range of $2.80 to $3.00.

Revenues $59.5 to $62.5 billion

Adjusted(4) SI&A Expenses

$12.5 to $13.5 billion

Adjusted(4) R&D Expenses

$10.5 to $11.5 billion

Effective Tax Rate on Adjusted(4) Income

Approximately 15.0%

Adjusted(4) Diluted EPS

$2.80 to $3.00

CAPITAL ALLOCATION

During the first three months of 2026, Pfizer deployed its capital in a variety of ways, which primarily included:

▪Reinvesting capital into initiatives intended to enhance the future growth prospects of the company, including:

•$2.5 billion invested in internal research and development projects, and

•Approximately $110 million invested in business development transactions.

▪Returning capital directly to shareholders through $2.4 billion of cash dividends, or $0.43 per share of common stock.

Our capital allocation framework is designed to enhance long-term shareholder value, and is based on three core pillars: (i) reinvesting in the business, including maintaining the flexibility to deploy capital towards potential value-creating business development transactions, (ii) maintaining and, over the long term, growing our dividend, and (iii) in the future, the potential to resume the return of capital to shareholders through value-enhancing share repurchases after de-levering our balance sheet. The company expe